Integra LifeSciences (NASDAQ:IART) Navigates Q3 2026 with Revenue Growth Amidst Price Target Adjustment
Wells Fargo adjusted its price target for Integra LifeSciences, reflecting a new analyst outlook for the medical products stock. Integra LifeSciences reported a Q3 2026 revenue increase of 2.3% to $411.20 million, alongside a significant rise in diluted earnings per share to $0.19. The company…